Fol. Biol. 2023, 69, 91-98
https://doi.org/10.14712/fb2023069030091
Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients
References
1. 2020) Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. J. Thorac. Oncol. Surg. 15, 1624-1635.
< , A., Faivre-Finn, C., Kennedy, J. et al. (https://doi.org/10.1016/j.jtho.2020.06.008>
2. 2019) The implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists. Int. J. Radiat. Oncol. Biol. Phys. 105, 698-712.
< , C., West, C. M., Higginson, D. S. et al. (https://doi.org/10.1016/j.ijrobp.2019.07.026>
3. 2022) Breast radiation therapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing. Int. J. Radiat. Oncol. Biol. Phys. 112, 437-444.
< , B. V., Liu, D., Shen, Y. et al. (https://doi.org/10.1016/j.ijrobp.2021.09.026>
4. 2021) Risk factors for radiation-induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy. Ann. Transl. Med. 9, 1288.
< , F., Yu, H., Zhang, H. et al. (https://doi.org/10.21037/atm-21-2150>
5. 2021) The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 111, 936-948.
< , P. J. J., Kroese, T. E., Van Hillegersberg, R. et al. (https://doi.org/10.1016/j.ijrobp.2021.07.1695>
6. 2020) Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci. Rep. 10, 7073.
< , S., Peron, J., Vuilleumier, A. et al. (https://doi.org/10.1038/s41598-020-63759-1>
7. 2015) Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 1, 943-951.
< , A., Kurian, A. W., Gabree, M. et al. (https://doi.org/10.1001/jamaoncol.2015.2690>
8. Edge, S., Byrd, D. R., Compton, C. C. et al. (2010) AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual, 7th ed. Springer-Verlag, Berlin/Heidelberg.
9. 2018) RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients. Int. J. Cancer 143, 1935-1942.
< , C., Zhang, J., Ouyang, T. et al. (https://doi.org/10.1002/ijc.31579>
10. 2021) Cancer statistics for the year 2020: an overview. Int. J. Cancer 149, 778-789.
< , J., Colombet, M., Soerjomataram, I. et al. (https://doi.org/10.1002/ijc.33588>
11. 2022) An overview on radiation sensitivity in hereditary breast and ovarian cancer syndrome. Cancers (Basel) 14, 3254.
< , D., Pires, A. S., Marques, I. A., Gomes, I. et al. (https://doi.org/10.3390/cancers14133254>
12. 2016) Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast 28, 136-144.
< , Z., Kristensen, V. N. (https://doi.org/10.1016/j.breast.2016.05.006>
13. 2019) Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int. J. Cancer 145, 1782-1797.
< , P., Stolarova, L., Krizova, K. et al. (https://doi.org/10.1002/ijc.32385>
14. 2023) Germline multigene panel testing of patients with endometrial cancer. Oncol. Lett. 25, 216.
< , J., Jelinkova, S., Zemankova, P. et al. (https://doi.org/10.3892/ol.2023.13802>
15. 2021) Breast cancer adjuvant radiotherapy in BRCA1/2, TP53, ATM genes mutations: are there solved issues? Breast Cancer (Dove Med. Press) 13, 299-310.
, G., Buono, G., Zannino, B. et al. (
16. 2020) Multigene panel germline testing of 1333 Czech patients with ovarian cancer. Cancers (Basel) 12, 956.
< , K., Stolarova, L., Zemankova, P. et al. (https://doi.org/10.3390/cancers12040956>
17. 2022) Severe radiation-induced lymphopenia during postoperative radiotherapy or chemoradiotherapy has poor prognosis in patients with stage IIB-III after radical esophagectomy: a post hoc analysis of a randomized controlled trial. Front. Oncol. 12, 936684.
< , W., Xiao, Z., Zhou, Z. et al. (https://doi.org/10.3389/fonc.2022.936684>
18. 2011) Radiotherapy in the treatment of hereditary breast cancer. Semin. Radiat. Oncol. 21, 43-50.
< , L. J., Haffty, B. G. (https://doi.org/10.1016/j.semradonc.2010.08.008>
19. 2009) Clinical radiation sensitivity with DNA repair disorders: an overview. Int. J. Radiat. Oncol. Biol. Phys. 74, 1323-1331.
< , J. M., Gatti, R. A. (https://doi.org/10.1016/j.ijrobp.2009.02.057>
20. 2020) Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants and risk of contralateral breast cancer. J. Natl. Cancer Inst. 112, 1275-1279.
< , A. S., Robson, M. E., Mellemkjćr, L. et al. (https://doi.org/10.1093/jnci/djaa031>
21. 2016) CZECANCA: CZEch CAncer paNel for Clinical Application – design and optimization of the targeted sequencing panel for the identification of cancer susceptibility in high-risk individuals from the Czech Republic. Klin. Onkol. 29, S46-S54. (in Czech)
< , J., Zemánková, Z., Kleiblová, P. et al. (https://doi.org/10.14735/amko2016S46>
22. 2018) Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One 13, e0195761.
< , J., Zemankova, P., Lhotova, K. et al. (https://doi.org/10.1371/journal.pone.0195761>
23. 2020) Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 108, 277-285.
< , G. Y., Wang, S. L., Song, Y. W. et al. (https://doi.org/10.1016/j.ijrobp.2020.02.633>
24. 2020) Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J. Clin. Oncol. 38, 2080-2106.
< , N. M., Boughey, J. C., Pierce, L. J. et al. (https://doi.org/10.1200/JCO.20.00299>
25. 2018) A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit. Rev. Oncol. Hematol. 123, 42-51.
< , B. P., Mallick, S., Lin, S. H. et al. (https://doi.org/10.1016/j.critrevonc.2018.01.003>
26. 2019) Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1/BRCA2 mutation carriers versus non-carriers. Cancers (Basel) 11, 738.
< , M., Zimovjanova, M., Bielcikova, Z. et al. (https://doi.org/10.3390/cancers11060738>
27. 2020) Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count. Radiat. Oncol. 15, 65.
< , X., Gong, S., Jin, H. et al. (https://doi.org/10.1186/s13014-020-01494-7>